Logo

ER/PgR

Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial

The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.

Coding Variants in Five Breast Cancer Risk Genes Linked to Contralateral Breast Cancer

Researchers characterized contralateral breast cancer risk and breast cancer survival patterns associated with coding germline variants in known breast cancer-related genes.

Breast Cancer Genomic Recurrence Signature Influenced by BMI in Young Patients

In younger Korean women with estrogen receptor-positive, HER2/ERBB2-negative breast cancer, higher body mass index appeared to coincide with a higher Oncotype Dx recurrence score.

Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy

A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and

New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes
Premium

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.